Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

IL-15Rα membrane anchorage in either cis or trans is required for stabilization of IL-15 and optimal signaling.

Quéméner A, Morisseau S, Sousa RP, Trillet K, Maillasson M, Leray I, Jacques Y, Dion J, Barbieux I, Frutoso M, Laurent AD, Le Questel JY, Mortier E.

J Cell Sci. 2019 Dec 5;133(5). pii: jcs236802. doi: 10.1242/jcs.236802.

PMID:
31653781
2.

Mechanistic and Structural Insights on the IL-15 System through Molecular Dynamics Simulations.

Sousa RP, Laurent AD, Quéméner A, Mortier E, Questel JL.

Molecules. 2019 Sep 6;24(18). pii: E3261. doi: 10.3390/molecules24183261.

3.

Emergence of NK Cell Hyporesponsiveness after Two IL-15 Stimulation Cycles.

Frutoso M, Morisseau S, Tamzalit F, Quéméner A, Meghnem D, Leray I, Jacques Y, Mortier E.

J Immunol. 2018 Jul 15;201(2):493-506. doi: 10.4049/jimmunol.1800086. Epub 2018 May 30.

4.

Two novel variants of uncertain significance in GP9 associated with Bernard-Soulier syndrome: Are they true mutations?

Boisseau P, Debord C, Eveillard M, Quéméner A, Sigaud M, Giraud M, Talarmain P, Thomas C, Landeau G, Bezieau S, Petesch BP, Béné MC, Fouassier M.

Platelets. 2018 May;29(3):316-318. doi: 10.1080/09537104.2017.1371288. Epub 2017 Nov 9.

PMID:
29119855
5.

Discovery of a Small-Molecule Inhibitor of Interleukin 15: Pharmacophore-Based Virtual Screening and Hit Optimization.

Quéméner A, Maillasson M, Arzel L, Sicard B, Vomiandry R, Mortier E, Dubreuil D, Jacques Y, Lebreton J, Mathé-Allainmat M.

J Med Chem. 2017 Jul 27;60(14):6249-6272. doi: 10.1021/acs.jmedchem.7b00485. Epub 2017 Jul 18.

PMID:
28657314
6.

Cutting Edge: Differential Fine-Tuning of IL-2- and IL-15-Dependent Functions by Targeting Their Common IL-2/15Rβ/γc Receptor.

Meghnem D, Morisseau S, Frutoso M, Trillet K, Maillasson M, Barbieux I, Khaddage S, Leray I, Hildinger M, Quéméner A, Jacques Y, Mortier E.

J Immunol. 2017 Jun 15;198(12):4563-4568. doi: 10.4049/jimmunol.1700046. Epub 2017 May 15.

7.

Molecular evolution and antigenic variation of European brown hare syndrome virus (EBHSV).

Lopes AM, Capucci L, Gavier-Widén D, Le Gall-Reculé G, Brocchi E, Barbieri I, Quéméner A, Le Pendu J, Geoghegan JL, Holmes EC, Esteves PJ, Abrantes J.

Virology. 2014 Nov;468-470:104-112. doi: 10.1016/j.virol.2014.08.002. Epub 2014 Aug 23.

8.

Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.

Vincent M, Teppaz G, Lajoie L, Solé V, Bessard A, Maillasson M, Loisel S, Béchard D, Clémenceau B, Thibault G, Garrigue-Antar L, Jacques Y, Quéméner A.

MAbs. 2014 Jul-Aug;6(4):1026-37.

9.

Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI.

Vincent M, Quéméner A, Jacques Y.

Oncoimmunology. 2013 Nov 1;2(11):e26441. Epub 2013 Oct 9.

10.

Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.

Vincent M, Bessard A, Cochonneau D, Teppaz G, Solé V, Maillasson M, Birklé S, Garrigue-Antar L, Quéméner A, Jacques Y.

Int J Cancer. 2013 Aug 1;133(3):757-65. doi: 10.1002/ijc.28059. Epub 2013 Feb 25.

11.

[The culture of Gypsy travellers in France].

Quémener A.

Rev Infirm. 2012 Apr;(180):18-9. French.

PMID:
22606770
12.

Prevalence, biological phenotype and genotype in moderate/mild hemophilia A with discrepancy between one-stage and chromogenic factor VIII activity.

Trossaërt M, Boisseau P, Quemener A, Sigaud M, Fouassier M, Ternisien C, Lefrançois-Bettembourg A, Tesson C, Thomas C, Bezieau S.

J Thromb Haemost. 2011 Mar;9(3):524-30. doi: 10.1111/j.1538-7836.2010.04174.x.

13.

Evolution of interleukin-15 for higher E. coli expression and solubility.

Béhar G, Solé V, Defontaine A, Maillasson M, Quéméner A, Jacques Y, Tellier C.

Protein Eng Des Sel. 2011 Mar;24(3):283-90. doi: 10.1093/protein/gzq107. Epub 2010 Nov 25.

PMID:
21109548
14.

High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer.

Bessard A, Solé V, Bouchaud G, Quéméner A, Jacques Y.

Mol Cancer Ther. 2009 Sep;8(9):2736-45. doi: 10.1158/1535-7163.MCT-09-0275. Epub 2009 Sep 1.

15.

The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha.

Bouchaud G, Garrigue-Antar L, Solé V, Quéméner A, Boublik Y, Mortier E, Perdreau H, Jacques Y, Plet A.

J Mol Biol. 2008 Sep 26;382(1):1-12. doi: 10.1016/j.jmb.2008.07.019. Epub 2008 Jul 16.

PMID:
18656487
16.

Docking of human interleukin-15 to its specific receptor alpha chain: correlation between molecular modeling and mutagenesis experimental data.

Quéméner A, Bernard J, Mortier E, Plet A, Jacques Y, Tran V.

Proteins. 2006 Nov 15;65(3):623-36.

PMID:
17001647
17.

Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins.

Mortier E, Quéméner A, Vusio P, Lorenzen I, Boublik Y, Grötzinger J, Plet A, Jacques Y.

J Biol Chem. 2006 Jan 20;281(3):1612-9. Epub 2005 Nov 11.

18.

Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity.

Rabu C, Quéméner A, Jacques Y, Echasserieau K, Vusio P, Lang F.

J Biol Chem. 2005 Dec 16;280(50):41472-81. Epub 2005 Oct 4.

19.

Identification of an interleukin-15alpha receptor-binding site on human interleukin-15.

Bernard J, Harb C, Mortier E, Quéméner A, Meloen RH, Vermot-Desroches C, Wijdeness J, van Dijken P, Grötzinger J, Slootstra JW, Plet A, Jacques Y.

J Biol Chem. 2004 Jun 4;279(23):24313-22. Epub 2004 Mar 23.

20.

Unexpected ultrasonographic prenatal diagnosis of autosomal dominant polycystic kidney disease.

Journel H, Guyot C, Barc RM, Belbeoch P, Quemener A, Jouan H.

Prenat Diagn. 1989 Sep;9(9):663-71. Review.

PMID:
2678088

Supplemental Content

Loading ...
Support Center